Q-omics provides the consensus-scored MFSD14C profile across patient tissues and cancer cell-line models. MFSD14C expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, MFSD14C is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, MFSD14C RNA expression shows 19,512 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and COAD as cancer lineages where MFSD14C shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MFSD14C — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MFSD14C survival associations across molecular data types. MFSD14C RNA expression shows survival associations in the most cancer types (26), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MFSD14C RNA expression–survival associations across cancer types. High MFSD14C expression shows unfavorable associations in ACC, COAD, LIHC, HNSC and UVM, but favorable associations in THYM. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify ACC as the clearest survival context for MFSD14C RNA expression.
This table summarizes MFSD14C tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for MFSD14C. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MFSD14C shows lower tumor expression in THCA and KIRC and higher tumor expression in COAD, HNSC, LIHC and BLCA. The COAD box plot shows higher MFSD14C RNA expression in tumor versus normal tissue (log2 FC = +0.872, t-test p < 0.001).
This table shows molecular features associated with MFSD14C in patient tissues and cancer cell lines. In patient samples, MFSD14C shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, MFSD14C RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia.
